{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:04:52Z","timestamp":1790287492515,"version":"4.1.0"},"reference-count":22,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Market Access & Health Policy"],"published-print":{"date-parts":[[2019,1,1]]},"DOI":"10.1080\/20016689.2019.1648971","type":"journal-article","created":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T06:44:39Z","timestamp":1564555479000},"page":"1648971","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of health technology assessment for new medicines in France and England: an example based on ixazomib for patients with relapsed or refractory multiple myeloma"],"prefix":"10.3390","volume":"7","author":[{"given":"Xavier","family":"Armoiry","sequence":"first","affiliation":[{"name":"Pharmacy Department, University of Lyon, School of Pharmacy (ISPB)\/UMR CNRS 5510 MATEIS\/Lyon University Hospitals, \u201cEdouard Herriot\u201d Hospital, Lyon, France"},{"name":"Warwick Medical School, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Martin","family":"Spath","sequence":"additional","affiliation":[{"name":"University Claude Bernard Lyon 1, University of Lyon, EA 4129 P2S (Parcours, Sant\u00e9, Syst\u00e9mique), Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8299-3146","authenticated-orcid":false,"given":"Aileen","family":"Clarke","sequence":"additional","affiliation":[{"name":"Warwick Medical School, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Connock","sequence":"additional","affiliation":[{"name":"Warwick Medical School, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sutcliffe","sequence":"additional","affiliation":[{"name":"Warwick Medical School, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Dussart","sequence":"additional","affiliation":[{"name":"University Claude Bernard Lyon 1, University of Lyon, EA 4129 P2S (Parcours, Sant\u00e9, Syst\u00e9mique), Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,7,30]]},"reference":[{"key":"CIT0001","unstructured":"Ninlaro | European Medicines Agency. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ninlaro"},{"key":"CIT0002","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 - NINLARO (ixazomib), antin\u00e9oplasique. Available from: https:\/\/www.has-sante.fr\/portail\/jcms\/c_2779830\/fr\/ninlaro-ixazomib-antineoplasique"},{"key":"CIT0003","unstructured":"National Institute for Health and Care Excellence (NICE), Topic selection | Our programmes | What we do | About. Available from: https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/topic-selection"},{"key":"CIT0004","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 - Commission de la transparence. Available from: https:\/\/www.has-sante.fr\/portail\/jcms\/c_412210\/fr\/commission-de-la-transparence"},{"key":"CIT0005","unstructured":"National institute for health and care excellence: overview of technology appraisals for patient and carer organisations, Public Involvement Programme. April 2014. Available from: https:\/\/www.nice.org.uk\/Media\/Default\/About\/NICE-Communities\/Public-involvement\/Developing-NICE-guidance\/Overview-of-technology-appraisals-patient-carer-groups.pdf"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826090-00004"},{"key":"CIT0007","unstructured":"National Institute for Health and Care Excellence (NICE), Patient access schemes, commercial access agreements and flexible pricing | Guide to the processes of technology appraisal | Guidance | NICE. Available from: https:\/\/www.nice.org.uk\/process\/pmg19\/chapter\/patient-access-schemes-commercial-access-agreements-and-flexible-pricing"},{"key":"CIT0008","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 - Le service m\u00e9dical rendu (SMR) et l\u2019am\u00e9lioration du service m\u00e9dical rendu (ASMR). Available from: https:\/\/www.has-sante.fr\/portail\/jcms\/r_1506267\/fr\/le-service-medical-rendu-smr-et-l-amelioration-du-service-medical-rendu-asmr"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharma.2017.04.005"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2017.1344088"},{"key":"CIT0011","volume-title":"Haute Autorit\u00e9 de Sant\u00e9: L\u2019\u00e9valuation m\u00e9dico-\u00e9conomique des M\u00e9dicaments et Dispositifs M\u00e9dicaux","year":"2014"},{"key":"CIT0012","unstructured":"National Institute for Health and Care Excellence (NICE), Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma | Guidance and guidelines | NICE. Available from: https:\/\/www.nice.org.uk\/guidance\/ta505"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"CIT0014","unstructured":"Direction G\u00e9n\u00e9rale de l'Offre de Soins (DGOS): Le forfait innovation. Available from: https:\/\/solidarites-sante.gouv.fr\/systeme-de-sante-et-medico-social\/recherche-et-innovation\/forfait-innovation"},{"key":"CIT0015","unstructured":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9 \u00e0 la r\u00e9f\u00e9rence, Qu\u2019est ce qu\u2019une autorisation temporaire d\u2019utilisation? ANSM: Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9. Available from: https:\/\/www.ansm.sante.fr\/Activites\/Autorisations-temporaires-d-utilisation-ATU\/Qu-est-ce-qu-une-autorisation-temporaire-d-utilisation\/(offset)\/0"},{"key":"CIT0016","unstructured":"Haute Autorit\u00e9 de Sant\u00e9, NINLARO 17052017 CT15988 TRANSCRIPTION. Available from: https:\/\/www.has-sante.fr\/portail\/plugins\/ModuleXitiKLEE\/types\/FileDocument\/doXiti.jsp?id=c_2803717"},{"key":"CIT0017","unstructured":"National Institute for Health and Care Excellence (NICE), Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma | Final Scope | NICE. Available from: https:\/\/www.nice.org.uk\/guidance\/ta505\/history"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0644-3"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.20552"},{"key":"CIT0020","unstructured":"Haute Autorit\u00e9 de Sant\u00e9,COMPTE RENDU CT 17052017. Available from: https:\/\/www.has-sante.fr\/portail\/plugins\/ModuleXitiKLEE\/types\/FileDocument\/doXiti.jsp?id=c_2775511"},{"key":"CIT0021","unstructured":"Avis relatif aux prix de sp\u00e9cialit\u00e9s pharmaceutiques, JORF n\u00b00252 du 31 octobre 2018 texte n\u00b0 142, https:\/\/www.legifrance.gouv.fr\/affichTexte.do?cidTexte=JORFTEXT000037543195&categorieLien=id."},{"key":"CIT0022","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 - La commission de la transparence pr\u00e9cise et adapte ses principes d\u2019\u00e9valuation des m\u00e9dicaments. Available from: https:\/\/www.has-sante.fr\/portail\/jcms\/c_2877573\/fr\/la-commission-de-la-transparence-precise-et-adapte-ses-principes-d-evaluation-des-medicaments"}],"container-title":["Journal of Market Access & Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/20016689.2019.1648971","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T09:02:52Z","timestamp":1705568572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/search?q=10.1080\/20016689.2019.1648971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1,1]]}},"alternative-id":["10.1080\/20016689.2019.1648971"],"URL":"https:\/\/doi.org\/10.1080\/20016689.2019.1648971","relation":{},"ISSN":["2001-6689"],"issn-type":[{"value":"2001-6689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=zjma20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=zjma20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-02-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}